---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-217439"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:38:34.687816+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics announces FDA lifts clinical hold on FTX-6058 IND for sickle cell disease

## Summary
- FDA lifted clinical hold on Fulcrum's IND for FTX-6058 on August 22, 2023.
- FTX-6058 is a potential treatment for sickle cell disease.
- Fulcrum posted a presentation with amended protocol and planned Phase 1b trial details.
- Clinical development can now resume; no financial terms disclosed.

## SEC filing metadata
- accession: 0001193125-23-217439
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312523217439/0001193125-23-217439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312523217439/d544132d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-217439
- JSON: https://secwatch.observer/filing/0001193125-23-217439.json
- Plain text: https://secwatch.observer/filing/0001193125-23-217439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.